In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme

HealthTech approach

HealthTech approach

Advice programme

Area of interest

Showing 201 to 250 of 387

TitleTypeExpected publication date
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513Technology appraisal guidanceTBC
Middle meningeal artery embolisation for chronic subdural haematomasInterventional procedures guidance
Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]Technology appraisal guidance
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]Technology appraisal guidanceTBC
Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]Technology appraisal guidance
MMprofiler for estimating risk in newly diagnosed multiple myelomaHealthTech guidance
Monofocal intraocular lenses for cataract surgeryHealth technology evaluation
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [TSID12203]Technology appraisal guidanceTBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]Technology appraisal guidanceTBC
Multidisciplinary care of children and young people with achondroplasiaNICE review
Nemolizumab for treating prurigo nodularis [ID6451]Technology appraisal guidanceTBC
Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]Technology appraisal guidance
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]Technology appraisal guidanceTBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]Technology appraisal guidance
Neurostimulation of lumbar muscles for refractory non-specific chronic low back painHealthTech guidanceTBC
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]Technology appraisal guidanceTBC
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]Technology appraisal guidanceTBC
Nirogacestat for treating desmoid tumours [ID6453]Technology appraisal guidance
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]Technology appraisal guidance
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]Technology appraisal guidanceTBC
Nivolumab in combination for untreated advanced classical Hodgkin lymphoma in people 12 years and over [ID6690]Technology appraisal guidanceTBC
Nivolumab with brentuximab vedotin for treating CD30-positive relapsed or refractory classical Hodgkin lymphoma after 1 treatment line in people 5 years and over [ID6691]Technology appraisal guidanceTBC
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]Technology appraisal guidance
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]Technology appraisal guidanceTBC
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]Technology appraisal guidanceTBC
Non-invasive skin closure devices for surgical incisions (MT775)Medical technologies guidanceTBC
Norucholic acid for treating primary sclerosing cholangitis [ID6583]Technology appraisal guidanceTBC
NY-ESO-1 T-cells for treating synovial sarcoma [ID1286]Technology appraisal guidanceTBC
Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519]Technology appraisal guidance
Obinutuzumab for treating serologically active extra-renal lupus [ID6670]Technology appraisal guidance
Obsessive-compulsive disorder and body dysmorphic disorderQuality standard
Obsessive-compulsive disorder and body dysmorphic disorder: assessment and managementNICE guideline
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]Technology appraisal guidanceTBC
Olezarsen for treating familial chylomicronaemia syndrome [ID6585]Technology appraisal guidance
Omburtamab for treating relapsed neuroblastoma [ID1664]Technology appraisal guidanceTBC
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease [TSID11941]Technology appraisal guidanceTBC
Optical Coherence Tomography to guide percutaneous coronary interventionInterventional procedures guidanceTBC
Orforglipron for managing overweight and obesity [ID6516]Technology appraisal guidance
Orthopaedic Guidelines on Management of Duchenne Muscular Dystrophy: DMD Care UK standard of care guidelineNICE review
Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472]Technology appraisal guidanceTBC
OsteoporosisQuality standardTBC
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)NICE guideline
Oveporexton for treating type 1 narcolepsy [ID6622]Technology appraisal guidanceTBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]Technology appraisal guidanceTBC
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]Technology appraisal guidance
Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]Technology appraisal guidanceTBC
Peezy Midstream for urine collection (MT446)Medical technologies guidanceTBC
Pegcetacoplan for amyotrophic lateral sclerosis [TSID10594]Technology appraisal guidanceTBC
Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]Technology appraisal guidanceTBC
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All